Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abbott Medical Devices
Demonstrate the safety and efficacy of the St. Jude Medical Radiofrequency (RF) Renal Denervation System in the treatment of patients with resistant hypertension.
Safety Marker
* All adverse events
Efficacy Marker
* Office blood pressure
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Office systolic blood pressure that remains ≥160 mmHg (≥150 mmHg for patient with type 2 diabetes) despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic, for a minimum of 14 days prior to enrollment
Age ≥18 and ≤80 years old
Able and willing to provide written informed consent to participate in the study
Able and willing to comply with the required follow-up schedule
You may not be if
Prior renal artery intervention (balloon angioplasty or stenting)
Evidence of renal artery atherosclerosis (defined as a stenotic severity of \>30%) in either renal artery
Multiple main renal arteries in either kidney
Main renal arteries \<4 mm in diameter or \<20 mm in length
eGFR of \<45 mL/min per 1.73 m2 using the MDRD formula
Type 1 diabetes
Renovascular hypertension or hypertension secondary to other renal disorders (glomerulonephritis, polycystic kidney disease, end-stage renal failure)
Others
Clareo Health | Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
